Free Newsletter
Sources: EQT Partners to team with Actavis in Ratiopharm bid
Free newsletter via e-mail
Tools
EQT Partners AB, the last private-equity bidder for German generic-drug maker Ratiopharm GmbH, is seeking to team up with Actavis Group to bolster its chances of beating large pharmaceutical companies like Pfizer in the auction, said three people familiar with the matter. Report
More stories about Ratiopharm
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: